首页>
外文期刊>Cell metabolism
>SGLT2 Inhibition with Empaglif lozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus
【24h】
SGLT2 Inhibition with Empaglif lozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus
展开▼
机译：SGLT2 Inhibition with Empaglif lozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus
Recent cardiovascular outcome trials with type 2 diabetes mellitus (T2DM) cohorts have shown that the use of sodium-glucose co-transporter 2 (SGLT2) inhibitors is associated with a decrease in major adverse cardiovascular events (MACE) (Zelniker et al., 2019). In the EMPA-REG OUTCOME trial, which followed individuals with T2DM and established atherosclerosis, the SGLT2 inhibitor empagliflo-zin (EMPA) reduced MACE by 14, all-cause mortality by 32, and hospitaliza-tion for heart failure by 35 (Verma et al., 2018; Zinman et al., 2015). The mechanisms through which SGLT2 inhibitors reduce vascular events remain unclear.
展开▼
